跳轉至內容
Merck
全部照片(1)

Key Documents

890810C

Avanti

18:0 DDAB

Avanti Research - A Croda Brand 890810C

同義詞:

Dimethyldioctadecylammonium (Bromide Salt)

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C38H80NBr
CAS號碼:
分子量::
630.95
分類程式碼代碼:
12352211
NACRES:
NA.25

形狀

liquid

包裝

pkg of 1 × 2.5 mL (890810C-25mg)
pkg of 2 × 4 mL (890810C-200mg)

製造商/商標名

Avanti Research - A Croda Brand 890810C

濃度

10 mg/mL (890810C-25mg)
25 mg/mL (890810C-200mg)

脂質類型

cationic lipids
transfection

運輸包裝

dry ice

儲存溫度

−20°C

SMILES 字串

CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]

InChI

1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1

InChI 密鑰

PSLWZOIUBRXAQW-UHFFFAOYSA-M

一般說明

18:0 DDAB is a cationic lipid and a quaternary ammonium salt. The hydrocarbon tails are saturated, unlike the ionizable lipids. 18:0 DDAB acts as an active nasal adjuvant.

應用

18:0 DDAB or Dimethyldioctadecylammonium (Bromide Salt) has been used to perform transfection of S2 cells.

生化/生理作用

18:0 DDAB is a surface-active molecule, used as an adjuvant to induce a systemic immune response. It is non-toxic.

包裝

5 mL Clear Glass Sealed Ampule (890810C-200mg)
5 mL Clear Glass Sealed Ampule (890810C-25mg)

其他說明

For R&D use only. Not for drug, household, or other uses.

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

也與該產品經常一起購買

產品號碼
描述
訂價

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

標靶器官

Central nervous system, Liver,Kidney

水污染物質分類(WGK)

WGK 3


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Sarah E McNeil et al.
Journal of pharmaceutical sciences, 100(5), 1856-1865 (2011-03-05)
The adjuvanticity of liposomes can be directed through formulation to develop a safe yet potent vaccine candidate. With the addition of the cationic lipid dimethyldioctadecylammonium bromide (DDA) to stable neutral distearoylphosphatidylcholine (DSPC):cholesterol (Chol) liposomes, vesicle size reduces while protein entrapment
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Anne Gallez et al.
International journal of pharmaceutics, 573, 118861-118861 (2019-11-26)
The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the incomplete understanding of nano-bio interactions. Specifically, the impact that inclusion
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務